BIONET Corp.
BIONET Corp. – 25 Years of Leadership in AI-Driven Exosome Technology, Precision Health, and Regenerative Medicine, Pioneering Biotech Innovation in Asia.
Our Companies
-
BIONET Corp. (1784): Founded in 1999, Taiwan’s first publicly listed stem cell company.
-
GGA Corp. (4160): Founded in 2008, Taiwan’s first publicly listed company specializing in precision health and digital technology.
-
BIONET Therapeutics Corp. (7808): Founded in 2022, officially recognized under the "Biotechnology and Pharmaceutical" qualification review. The first company to pioneer Exosome technology and AI-driven research, set to be listed on the Emerging Stock Board in December 2024.
Our Impact
-
Collaborating with thousands of enterprises to drive AI-Exosome regenerative medicine innovation.
-
Providing services to 50% of newborns and 95% of gynecology and reproductive centers in Taiwan.
-
Partnering with 500+ medical institutions, facilitating over 850 stem cell transplants across 70+ disease applications. •Expanding operations to 17 countries, serving over 1.8 million customers worldwide.
Our Achievements
-
61 approved cell therapy projects under Taiwan's Ministry of Health and Welfare, including treatments utilizing adipose-derived mesenchymal stem cells for degenerative arthritis, knee cartilage defects, and chronic wounds, as well as immune cell (CIK) therapy for colorectal cancer, lung cancer, breast cancer, liver cancer, and more.
-
Leading the market in adipose-derived stem cell therapy, with 80% of nationwide patient enrollment and approvals.